Coffee May Decrease Risk of Malignant Melanoma
the Cancer Therapy Advisor take:
According to a new study published in the Journal of the National Cancer Institute, researchers from the National Cancer Institute Division of Cancer Epidemiology and Genetics have found that drinking coffee may decrease a person's risk for developing malignant melanoma.
Prior studies have shown that coffee consumption may reduce the risk of non-melanoma skin cancers, but data on its protective effect for cutaneous melanoma was lacking. Therefore, researchers sought to investigate if there is an association between coffee consumption and cutaneous melanoma (malignant and in situ).
Researchers identified over 447,000 non-Hispanic white subjects from the NIH-AARP Diet and Health Study. In that study, participants were surveyed about their food-frequency habits between 1995 and 1996 with a median follow-up of 10 years.
At baseline, all participants were cancer-free, and researchers adjusted for various risk factors, such as UV radiation exposure, age, alcohol intake, sex, smoking history, age, physical activity, and body mass index. Results showed that those who drank 4 or more cups of coffee per day had a 20% lower risk of melanoma.
In addition, researchers found that the protective benefits increased the more coffee a person drank, but only when the coffee was caffeinated and only for malignant melanoma. The researchers note that the further studies are warranted to confirm the results, and the findings may not be applicable to other populations.
Drinking coffee may decrease a person's risk for developing malignant melanoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models